EGFR and neoplasm: The only targeted therapy approved in the USA and European Union in the curative treatment setting is cetuximab, an EGFR-binding antibody whose mechanism of action has been suggested to be driven in large parts by triggering immunologic anti-tumor reactions and not predominantly by inhibition of the EGFR pathway [2].